See the video below as the Scientific American Worldview team and I discuss the latest edition of our global biotechnology profile and ranking. For more details you can download the entire magazine at http://www.saworldview.com.
 |
For Third Rock Ventures' Mark Levin, personalized medicine is nothing new. Instead, he sees the history of pharma as a gradual homing in on the roots of disease, and genomic mapping is just the next step. By Damien Garde, Fierce Biotech. From the herbal remedies of early civilizations to the dawn of modern pharmaceuticals, researchers have been slowly drilling down, Levin said, personalizing treatments one step at a time. Now, with the help of sequencing, we can move beyond treating phenotypic effects and get to the heart of disease: its genotypic origins. That is, if we can all get along. Levin spoke to a packed house Tuesday at the Personalized Medicine Coalition's State of Personalized Medicine Luncheon in Washington, DC, and his message was simple: Personalized medicine has the potential to revolutionize biotech and pharma, but only if stakeholders work together. Levin's had a long career in the industry, going from an engineer and project leader at Eli Lilly ($LLY) and Genentech to CEO of Millennium Pharmaceuticals. Since 2007, he's been at the helm of Third Rock Ventures, a VC firm that invests in and builds innovative biotech companies. Through 36 years in the field, Levin said he's seen the great promise of genomics inspire minds around the industry, only to be slowed by the usual suspects: companies unwilling to collaborate, regulators reluctant to cooperate and researchers getting a little ahead of themselves in the news media. Now, however, as the cost of <b>...</b> |
From:
CommercialBiotech
Views:
136
 0
ratings |
| Time: 07:32 | More in Science & Technology |
Rolf Taylor, the Journal of Commercial Biotechnology video blogger, recently interviewed Greg Stanley, Chief Commercialization Officer of Oncimmune, about engaging with smokers and ex-smokers on Facebook.
See his two-part interview below:
See more on OncImmune at their homepage or their YouTube channel.
 |
Part 2 of 2. Social media is becoming an important gateway to patients and consumers for biotechnology companies wishing to commercialize without the major investment required for a sales force. Greg Stanley, Chief Commercialization Officer of Oncimmune, talks to Journal of Commercial Biotechnology reporter Rolf Taylor about engaging with smokers and ex-smokers on Facebook. |
From:
CommercialBiotech
Views:
54
0
ratings |
| Time: 09:27 | More in Science & Technology |
 |
Part 1 of 2. Social media is becoming an important gateway to patients and consumers for biotechnology companies wishing to commercialize without the major investment required for a sales force. Greg Stanley, Chief Commercialization Officer of Oncimmune, talks to Journal of Commercial Biotechnology reporter Rolf Taylor about engaging with smokers and ex-smokers on Facebook. |
From:
CommercialBiotech
Views:
63
0
ratings |
| Time: 12:32 | More in Science & Technology |
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Recent Comments